Montelukast with levocetrizine Vs Montelukast with fexofenadine in allergic rhinitis.

Montelukast with levocetrizine Vs Montelukast with fexofenadine in allergic rhinitis:A randomised controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/063516

Enrollment

Registered

2024-03-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified

Interventions

Intervention1: Montelukast with levocetirizine: Montelukast is a highly selective leukotrine receptor antagonist levocetirizine is a second-generation histamine receptor antagonist. The duration of in

Eligibility

Inclusion criteria

Inclusion criteria: All patients willing to participate in the study Patients of both the genders within the age of 18 years to 60 years All patients diagnosed with allergic rhinitis

Exclusion criteria

Exclusion criteria: Female patients during pregnancy and lactation period Patients with hypertensive disorders,diabetes mellitus, thyroid dysfunction Patients with nasal mass or with a history of nasal surgery

Design outcomes

Primary

Measure	Time frame
Decrease in TOTAL NASAL SYMPTOM SCORETimepoint: 0, 2, and 4 week	—

Secondary

Measure	Time frame
improvement in quality of life, side effectsTimepoint: 0, 2, and 4 week	—

Countries

India

Contacts

Public ContactPriyanka pal

RMCH,Bareilly

drabhinavsrivastava7@gmai.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026